In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment algorithm is rapidly evolving, driven by the approval of multiple PARP inhibitors, including the market entry of Clovis Oncology’s Rubraca and Tesaro’s Zejula in the United States. Several areas of high unmet need—in particular, new treatment options for platinum-resistant or refractory ovarian cancer—offer significant commercial opportunity for innovative agents. Multiple immune checkpoint inhibitor combination therapies are in late-phase development for ovarian cancer and could significantly alter the treatment paradigm. This content provides insight on how treatment options for ovarian cancer are likely to change over the 2016-2026 forecast period. It also analyzes the current and future sales potential of drugs already in the market and those expected to be approved during the forecast period for ovarian ;
- We anticipate the ovarian cancer market will more than quadruple in size over the forecast period. What factors are set to drive market growth? Will anything constrain the ovarian cancer market? What challenges and opportunities remain?
- Three PARP inhibitors—Lynparza, Rubraca, and Zejula—are approved for ovarian cancer in the United States. How will each PARP inhibitor will be received in different markets based on its differing approvals? What other PARP inhibitors are set to launch? What is the size of the population eligible for PARP inhibitors? What sales will the PARP inhibitor drug class realize?
- What is the future landscape like for the angiogenesis inhibitor Avastin? Are any other angiogenesis inhibitors expected to launch? How will entry of biosimilar bevacizumab impact this drug class?
- Drug treatment of ovarian cancer remains centered on chemotherapy, leaving unmet need opportunities for drug development. What are the major areas of unmet need in ovarian cancer? Which areas may provide the highest commercial rewards? How are companies approaching drug development in ovarian cancer?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts; physician surveys fielded to approximately 30 physicians from each of the major markets who treat at least five ovarian cancer patients per month.
Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).
Population segments in market forecast: Early-stage first-line, advanced-stage first-line, second-line platinum-sensitive, second-line platinum-resistant, third-line, fourth and subsequent lines.
Market forecast features: Using a proprietary patient-flow model incorporating mortality, we forecast population sizes and drug sales for all patient segments through 2026.